Genmab (GMAB) has announced its decision to halt the clinical development of acasunlimab. This move aligns with the company's strategy to emphasize projects offering the most significant value to its late-stage portfolio. Despite positive clinical results so far, Genmab has opted to redirect resources to more promising ventures, such as EPKINLY, petosemtamab, and rinatabart sesutecan, which are advancing in development stages. This decision is part of Genmab's approach to disciplined portfolio management and capital allocation.
The company's leadership believes that focusing on these high-impact programs will maximize benefits for both patients and shareholders. Genmab's CEO, Jan van de Winkel, has expressed enthusiasm for the progress of these initiatives and commitment to their rapid and thorough execution. Importantly, this strategic adjustment does not affect Genmab's financial projections for the year 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.